Retrophin plots a $40M IPO amid a spree of deals

It's been a busy month for Retrophin ($RTRX), and CEO Martin Shkreli is capping it off with an IPO filing, looking to take his company from over-the-counter trading to the Nasdaq and pick up $40 million in the process. The biotech recently traded $5 million for Novartis' ($NVS) oxytocin nasal spray with hopes of developing the long-shelved drug into a treatment for schizophrenia and autism, a move that grabbed headlines--though many of them boiled down to "Is Retrophin for real?" The company's pipeline also includes a Phase II treatment for focal segmental glomerulosclerosis and early stage drugs targeting nephrotic syndrome, infantile spasms and neurodegeneration. Filing

Suggested Articles

Yale scientists have combined the gene-editing system CRISPR with gene therapy to help the immune system find tough-to-spot tumor cells.

The planned deal hit a wall when a special committee set up by Eidos turned down BridgeBio’s third and final offer.

Shares in ReNeuron fell more than one-third after the release of top-line data at the start of the month but the biotech argued the data are positive.